EP Patent

EP2617716A1 — Process for the preparation of bendamustine hydrochloride and related compounds

Assigned to Arevipharma GmbH · Expires 2013-07-24 · 13y expired

What this patent protects

Disclosed are processes for chlorination of the dihydroxy bendamustine precursor and the purification of bendamustine and related compounds.

USPTO Abstract

Disclosed are processes for chlorination of the dihydroxy bendamustine precursor and the purification of bendamustine and related compounds.

Drugs covered by this patent

bendamustine-hydrochloride (BENDAMUSTINE HYDROCHLORIDE)

Patent Metadata

Patent number: EP2617716A1
Jurisdiction: EP
Classification: —
Expires: 2013-07-24
Drug substance claim: No
Drug product claim: No
Assignee: Arevipharma GmbH
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.